Executive Summary
The Egyptian Vaccine Manufacturers Alliance (EVMA) represents a cornerstone in Egypt’s national strategy to localize vaccine manufacturing and strengthen the country’s health security architecture. Established as the executive arm of the National Strategy for Localizing Vaccine Production (2024–2030), EVMA unifies Egypt’s public and private vaccine manufacturers under a single coordinated platform, supported by the Unified Procurement Authority (UPA) and the Ministry of Health and Population (MoHP), and in collaboration with the Egyptian Drug Authority (EDA).
EVMA’s formation reflects Egypt’s commitment to transitioning from vaccine import dependency to a self-reliant, innovation-driven, and export-capable biomanufacturing ecosystem, aligned with Africa’s continental goal of producing 60% of its vaccine needs by 2040.
EVMA
In its inaugural year
Technology Transfer Agreements
Vaccine Products
Local Partnership Agreements
In its inaugural year, EVMA has already delivered unprecedented achievements:
- 9 technology transfer agreements, covering 18 vaccine products
- 3 local partnership agreements among Egyptian manufacturers to promote industrial integration
- Establishment of a quarterly implementation monitoring system to ensure transparency, accountability, and sustained progress
- Engagement with strategic international partners including WHO, Africa CDC, the EU, AVMA, and RCCN
EVMA positions Egypt as a regional leader in vaccine production, regulatory convergence, and health industrialization—advancing national interests while contributing to Africa’s collective health resilience.
1. National Context and Strategic Mandate
1.1 Presidential Directives and National Priorities
The establishment of EVMA stems directly from Presidential directives calling for the localization of essential biological industries and the strengthening of Egypt’s health sovereignty. These directives prioritize:
- Developing local biomanufacturing capacity
- Enabling rapid pandemic response capability
- Securing equitable national and regional vaccine access
- Reducing strategic import dependence
1.2 Prime Ministerial Decree No. 719 (2024)
This decree mandated the development of the National Strategy for Localizing Vaccine Production, providing legislative grounding for EVMA as its executive mechanism.
1.3 National Strategy Launch (27 November 2024)
The national strategy and EVMA were launched jointly in a historic event attended by:
- All relevant government authorities
- Over 9 global vaccine technology providers (from India, China, France, Denmark, the U.S., and the Netherlands)
- Key industrial partners
- International organizations
This marked the beginning of a coordinated, state-supported industrial transformation.
2. EVMA’s Establishment and Mandate
2.1 Purpose
EVMA is Egypt’s strategic platform for coordinating:
- Technology transfer
- Workforce development
- Regulatory alignment
- Local production pipelines
- Regional export pathways
EVMA ensures a unified national vision and an integrated implementation roadmap.
2.2 Members
EVMA includes Egypt’s principal vaccine manufacturers from both the public and private sectors, including:
- Egyptian Vaccine City
- VACSERA
- Genevax
- Biogeneric Pharma
- Egyptian Pharmaceutical City (GMP City)
- Eva Pharma
Oversight and support are provided by:
- Unified Procurement Authority (UPA)
- Ministry of Health and Population (MoHP)
- Egyptian Drug Authority (EDA)
International cooperation includes alignment with:
- WHO
- Africa CDC
- African Union
- RCCN (North Africa)
- European Union (EU)
- Global technology providers
EVMA | Egyptian Vaccine Manufacturers Alliance Key Partners
3. First-Year Achievements (2024–2025)
3.1 Technology Transfer Milestones
EVMA facilitated:
- 9 MoUs with global manufacturers
- Covering 18 vaccine products, including advanced platforms such as:
- mRNA
- Viral vector
- Inactivated vaccines
- Protein subunit vaccines
These agreements create the foundation for scalable, high-quality local production.
3.2 Industrial Integration Agreements
To promote synergy, reduce redundancy, and ensure efficient localization:
- 3 partnership agreements were signed between EVMA member companies to coordinate manufacturing roles and supply-chain integration.
3.3 Monitoring and Accountability Mechanisms
EVMA instituted:
- A quarterly progress report for technology transfer and production readiness
- A mechanism for rapid technical support and bottleneck resolution
3.4 International Cooperation and European Union Engagement
The European Union has provided:
- Technical cooperation
- Standards alignment support
- Capacity-building initiatives
This ensures Egypt’s vaccine manufacturing base adheres to international GMP and regulatory benchmarks.
3.5 Regional Leadership
EVMA advanced Egypt’s regional role through:
- Active participation in APPM (African Pooled Procurement Mechanism)
- Alignment with Africa CDC’s regulatory harmonization initiatives
- Integration into the RCCN for North Africa, strengthening regional regulatory convergence
4. Strategic Objectives (2025–2040)
EVMA’s strategic roadmap is structured across three time horizons:
4.1 Short-Term Goals (2025–2030)
- Localizing 50% of Egypt’s vaccine production
- Securing WHO Prequalification (PQ) for 10 vaccines
- Enhancing national pandemic readiness
- Establishing export readiness for priority vaccines
4.2 Medium-Term Goals (2030–2035)
- Achieving 75% localization of national vaccine needs
- Securing WHO PQ for 4 additional vaccines
- Strengthening Egypt’s position as a regional export hub
4.3 Long-Term Goals (2035–2040)
- Achieving 100% national self-sufficiency
- Expanding market penetration in Africa and the Middle East
- Increasing Egyptian vaccine exports by 50%
- Full integration into African vaccine manufacturing ecosystems
5. Governance and Operational Model
EVMA functions as an implementation alliance under UPA supervision. Its structure includes:
- UPA-led Executive Oversight
- Technical Working Groups (TWGs) in:
- Regulatory affairs
- Technology transfer
- Quality management
- Workforce development
- Export & market access
- Industry Liaison Committees
- International Partnership Desk
This model ensures cohesion between government, industry, and international partners.
6. Regional and Global Positioning
EVMA is an integral partner to Africa’s continental strategy.
It directly supports:
- AVMA (African Vaccine Manufacturing Accelerator)
- APPM
- Africa CDC’s Partnership for African Vaccine Manufacturing (PAVM)
- RCCN for North Africa
Through these collaborations, Egypt contributes to a continental manufacturing ecosystem that enhances Africa’s health resilience and reduces global dependency.
7. Strategic Impact
EVMA generates national and regional impact through:
- Strengthening Egypt’s biomedical industry
- Enhancing pandemic preparedness
- Increasing technology sovereignty
- Creating skilled jobs in advanced biomanufacturing
- Expanding Africa’s vaccine supply
- Supporting economic diversification and export growth
- Reinforcing Egypt’s role as a regional health security leader
The Egyptian Vaccine Manufacturers Alliance (EVMA) stands as a transformative national instrument to achieve self-reliance in vaccine production, secure Egypt’s health future, and elevate the country’s regional leadership.
Supported by robust political will, strategic partnerships, and a unified industrial ecosystem, EVMA positions Egypt to become a central hub for biological manufacturing—serving both national needs and the broader African continent.
EVMA is more than an alliance: It is a national mission, a continental partnership, and a commitment to future generations.
For more information visit: https://evma-egypt.org/
Press release about EVMA: https://evma-egypt.org/evma-conference-launch-release/
EVMA
In its inaugural year
Technology Transfer Agreements
Vaccine Products
Local Partnership Agreements